Mochida Pharmaceutical Co., Ltd. (TYO:4534)
Japan · Delayed Price · Currency is JPY 3,450.00
+35.00 (1.02%)
May 29, 2026, 3:30 PM JST
Mochida Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 116,951 | 105,159 | 102,885 | 103,261 | 110,179 | |
Revenue Growth (YoY) | 11.21% | 2.21% | -0.36% | -6.28% | 6.98% |
Cost of Revenue | 60,690 | 51,371 | 50,815 | 48,146 | 50,626 |
Gross Profit | 56,261 | 53,788 | 52,070 | 55,115 | 59,553 |
Selling, General & Admin | 46,113 | 33,985 | 33,713 | 33,324 | 32,866 |
Research & Development | - | 11,676 | 12,554 | 13,283 | 12,295 |
Operating Expenses | 46,113 | 45,661 | 46,267 | 46,607 | 45,161 |
Operating Income | 10,148 | 8,127 | 5,803 | 8,508 | 14,392 |
Interest Expense | -72 | -3 | -2 | - | - |
Interest & Investment Income | 567 | 420 | 365 | 340 | 286 |
Earnings From Equity Investments | 793 | -618 | -168 | - | - |
Currency Exchange Gain (Loss) | -242 | - | -60 | -36 | - |
Other Non Operating Income (Expenses) | 1 | 141 | 99 | 273 | 120 |
EBT Excluding Unusual Items | 11,195 | 8,067 | 6,037 | 9,085 | 14,798 |
Gain (Loss) on Sale of Investments | -24 | - | 100 | - | 526 |
Gain (Loss) on Sale of Assets | -1 | -15 | 22 | -54 | -5 |
Asset Writedown | - | - | - | - | -107 |
Other Unusual Items | - | - | 1 | 13 | -621 |
Pretax Income | 11,170 | 8,052 | 6,160 | 9,044 | 14,591 |
Income Tax Expense | 3,267 | 2,367 | 1,613 | 2,395 | 4,022 |
Net Income | 7,903 | 5,685 | 4,547 | 6,649 | 10,569 |
Net Income to Common | 7,903 | 5,685 | 4,547 | 6,649 | 10,569 |
Net Income Growth | 39.02% | 25.03% | -31.61% | -37.09% | 23.08% |
Shares Outstanding (Basic) | 35 | 35 | 36 | 37 | 38 |
Shares Outstanding (Diluted) | 35 | 35 | 36 | 37 | 38 |
Shares Change (YoY) | -0.00% | -1.15% | -3.49% | -2.47% | -1.37% |
EPS (Basic) | 222.93 | 160.36 | 126.79 | 178.93 | 277.39 |
EPS (Diluted) | 222.93 | 160.36 | 126.79 | 178.93 | 277.39 |
EPS Growth | 39.02% | 26.48% | -29.14% | -35.49% | 24.80% |
Free Cash Flow | -10,045 | 7,194 | -9,776 | 5,131 | 4,471 |
Free Cash Flow Per Share | -283.36 | 202.93 | -272.59 | 138.08 | 117.34 |
Dividend Per Share | - | 80.000 | 80.000 | 80.000 | 90.000 |
Dividend Growth | - | - | - | -11.11% | - |
Gross Margin | 48.11% | 51.15% | 50.61% | 53.37% | 54.05% |
Operating Margin | 8.68% | 7.73% | 5.64% | 8.24% | 13.06% |
Profit Margin | 6.76% | 5.41% | 4.42% | 6.44% | 9.59% |
Free Cash Flow Margin | -8.59% | 6.84% | -9.50% | 4.97% | 4.06% |
EBITDA | 13,127 | 11,067 | 8,611 | 11,180 | 17,081 |
EBITDA Margin | 11.22% | 10.52% | 8.37% | 10.83% | 15.50% |
D&A For EBITDA | 2,979 | 2,940 | 2,808 | 2,672 | 2,689 |
EBIT | 10,148 | 8,127 | 5,803 | 8,508 | 14,392 |
EBIT Margin | 8.68% | 7.73% | 5.64% | 8.24% | 13.06% |
Effective Tax Rate | 29.25% | 29.40% | 26.19% | 26.48% | 27.57% |
Advertising Expenses | - | 5,065 | 4,966 | - | 4,251 |